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Background: Rifampin is one of the most important drugs in first-line therapies for tuberculosis. The renal toxicity
of rifampin has been reported sporadically and acute tubulointerstitial nephritis (ATIN) is a frequent histological
finding. We describe for the first time a case of ATIN and Fanconi syndrome presenting as hypokalemic paralysis,
associated with the use of rifampin.
Case presentation: A 42-year-old man was admitted with sudden-onset lower extremity paralysis and mild renal
insufficiency. He had been treated for pulmonary tuberculosis with isoniazid, rifampin, and ethambutol for 2
months. Laboratory tests revealed proteinuria, profound hypokalemia, hyperchloremic metabolic acidosis with a
normal anion gap, positive urine anion gap, hypophosphatemia with hyperphosphaturia, hypouricemia with
hyperuricosuria, glycosuria with normal serum glucose level, generalized aminoaciduria, and β2-microglobulinuria. A
kidney biopsy revealed findings typical of ATIN and focal granular deposits of immunoglubulin A and complement
3 in the glomeruli and tubules. Electron microscopy showed epithelial foot process effacement and electron-dense
deposits in the subendothelial and mesangial spaces. Cessation of rifampin resolved the patient’s clinical
presentation of Fanconi syndrome, and improved his renal function and proteinuria.
Conclusion: This case demonstrates that rifampin therapy can be associated with Fanconi syndrome presenting as
hypokalemic paralysis, which is a manifestation of ATIN. Kidney function and the markers of proximal tubular injury
should be carefully monitored in patients receiving rifampin.
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Rifampin is one of the most effective antibiotics used for
the treatment of tuberculosis. The renal toxicity of rifam-
pin has been reported sporadically and acute renal failure
is a frequent clinical presentation [1]. Histologically, rifam-
pin nephrotoxicity is associated with acute tubulointersti-
tial nephritis (ATIN), tubular necrosis, papillary necrosis,
acute cortical necrosis, and minimal change disease [1-3].
Of these, ATIN and tubular necrosis are the most com-
mon and frequently develop upon reintroduction of the
drug or during intermittent therapy.* Correspondence: hwanghs@catholic.ac.kr
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reproduction in any medium, provided the orAcquired Fanconi syndrome occurs at any age as an
autoimmune disorder or after exposure to noxious
agents [4,5]. It is characterized by a generalized trans-
port defect in the proximal tubules and can be asso-
ciated with drug-induced ATIN [6-8]. However, neither
Fanconi syndrome nor associated hypokalemic paraly-
sis has ever been reported in patients with rifampin-
associated ATIN. We describe a case of ATIN and
Fanconi syndrome presenting as hypokalemic paralysis
in a patient receiving rifampin.Case presentation
A 42-year-old man was hospitalized with sudden-onset
weakness in both lower extremities. The patient had
been treated with isoniazid 300 mg, rifampin 450 mg,. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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during the past two months. He had no history of expos-
ure to antituberculosis antibiotics before beginning ther-
apy. His compliance to antibiotics was excellent after the
treatment for pulmonary tuberculosis and he denied the
interruption on these regimens. He reported no constitu-
tional symptoms, history of hyperthyroidism or paralysis.
A physical examination indicated that the muscle
strength of the lower extremities was 2/5 of normal. The
rest of the physical examination was unremarkable. A chest
radiograph revealed reticular opacities on the bilateral
upper lung fields, consistent with pulmonary tuberculosis.
His laboratory data included hemoglobin 13.0 mg/dL,
leukocyte count 9900/μL, and platelet count 290,000/μL.
His biochemical data for serum and urine on admission
are shown in Table 1. Profound hypokalemia, hypopho-
sphatemia, and hypouricemia were present. Serum pH, bi-
carbonate level and anion gap indicated hyperchloremicTable 1 Biochemical Data on Admission and after Rifampin W
Admission 2 weeks
Serum
Urea nitrogen (mg/dL) 13.9 -
Creatinine (mg/dL) 1.4 -
Potassium (mmol/L) 2.0 3.8
pH 7.289 7.260
Bicarbonate (mmol/L) 12.4 14.5
Phosphate (mg/dL) 1.2 2.7
Uric acid (mg/dL) 1.2 1.3
Sodium (mmol/L) 141 140
Chloride (mmol/L) 114 112
Magnesium (mg/dL) 2.1 2.3
Albumin (g/dL) 4.7 -
Urine
24-h glucose (g/day) 16.90 -
β2-microglobulin (μg/L)* >20000 -
Potassium (mEq/L) 7.2
Phosphate (mg/dL) 11.7








24-h protein (g/day) 2.50 0.91
Note: Replacement of potassium chloride and sodium bicarbonate was interrupted
*Normal, less than 370 mg/L.
† Normal, 4-16%.
‡Normal, 2.3 to 4.3.
§Normal, 6-20%.
FEK, fractional excretion of potassium; TmP/GFR, tubular maximal transport of phosp
excretion of uric acid.metabolic acidosis with normal anion gap. The urinary
anion gap was positive (10.2 mEq/L), suggesting the pres-
ence of renal tubular acidosis. Urinalysis showed normo-
glycemic glucosuria, β2-microglobulinuria, pH 5.5, 2.5 g/
day proteinuria and microscopic hematuria. The fractional
excretion of potassium was 29.3% (normal range, 4%–
16%); the calculated ratio of the maximal tubular transport
of phosphate reabsorption to the glomerular filtration rate
(TmP/GFR) was 0.24 mg/dL (normal range, 2.3–4.3 mg/
dL); and the fractional excretion of uric acid was 77.4%
(normal range, 6%–20%). Generalized hyperaminoaciduria
was detected with liquid chromatography–tandem mass
spectrometry. These findings suggest generalized proximal
tubular dysfunction with wasting of bicarbonate, glucose,
protein, potassium, phosphate, and uric acid.
Additional blood tests were performed to determine
other possible causes of the patient’s hypokalemia. His
plasma renin activity and serum level of aldosteroneithdrawal























at 3 months after admission.
hate reabsorption to the glomerular filtration rate transport; FEUA, fractional
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thyroid-stimulating hormone and free thyroxine levels
were within the normal ranges. Serum and urinary pro-
tein immunoelectrophoresis showed no evidence of
monoclonal gammopathy, and immunological surveys of
autoantibodies were negative. The patient’s reticulocyte
count, serum lactate dehydrogenase, and liver enzymes
levels were within the normal ranges.
An ultrasonographic examination showed a normal-
sized kidney, with slightly increased echogenicity in the




Figure 1 Pathologic findings in a patient with rifampin-associated acu
microscopy revealed the extensive mononuclear cell infiltrates including ep
tubular atrophy (A: original magnification X 100; B: original magnification x
immunoglobulin A (C) and complement 3 (D) in mesangial spaces and tub
mesangial spaces with electron dense deposits (F) were visible using electrextensive mononuclear cell infiltrates, including epithe-
lioid histiocytes and eosinophils, mild interstitial fibrosis,
and tubular atrophy (Figure 1A and B). Ziehl–Neelsen
staining for acid-fast bacilli and PCR detection of Myco-
bacterium tuberculosis in the renal biopsy specimen
were negative. Focal granular deposits of immunoglobu-
lin A (IgA) and complement 3 (C3) were demonstrated
in the tubules (Figure 1C and D). The same immuno-
fluorescent positivity was also shown in glomerular
mesangium, and electron microscopy showed electron-




te tubulointerstitial nephritis and Fanconi syndrome. Light
ithelioid histiocytes and eosinophils, mild interstitial fibrosis and
400). Immunofluorescent stains showed focal granular deposits of
ules. Subendothelial electron-dense deposits (E) and expanded
on microscopy.
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with IgA nephropathy accompanied by focal immune
deposits along the tubules. Half the epithelial foot pro-
cesses were effaced, and there were no pathological find-
ings in the mitochondria.
Potassium chloride supplementation was given to treat
the patient’s hypokalemic paralysis. His muscle strength
increased one day after potassium chloride supplementa-
tion. We substituted rifampin with levofloxacin, but his
other antituberculosis antibiotics remained the same. Sup-
plementation with potassium chloride and sodium bicar-
bonate was continued, and the patient was discharged on
hospital day 14. The biochemical markers associated with
Fanconi syndrome were significantly resolved, and he
experienced no paralytic symptoms after discharge. His
proteinuria and microscopic hematuria was also improved,
and we discontinued supplementation with potassium
chloride and sodium bicarbonate at the three-month fol-
low-up. The patient’s renal function and proximal tubular
function remained stable at the last follow-up.
Discussion
We have reported for the first time rifampin-associated
ATIN and Fanconi syndrome presenting as hypokalemic
paralysis. The typical findings of ATIN were present in a
kidney biopsy specimen from the patient, and general-
ized proximal tubular dysfunction was demonstrated by
his biochemical parameters. The symptoms of Fanconi
syndrome disappeared after the discontinuation of ri-
fampin, which strongly indicates that rifampin was the
causative agent of Fanconi syndrome.
The clinical manifestations of rifampin-associated
nephrotoxicity can be mainly classified into two groups,
depending on the anti-rifampin antibody induced [9,10].
In patients treated with an interrupted regimen, the
rifampin-dependent antibody produces acute tubular ne-
crosis requiring dialysis, intravascular hemolysis, and
flu-like symptoms. In contrast, the continuous adminis-
tration of rifampin has been described as progressing
more insidiously. In this setting, tests for anti-rifampin
antibody are uniformly negative, and the degree of inter-
stitial inflammation is much greater than that of acute
tubular necrosis [11]. Our patient had no history of prior
exposure to rifampin or interruption on regimen, and
reported no constitutional symptoms. Furthermore, the
results of a kidney biopsy were compatible with the lat-
ter condition. These findings suggest that ATIN oc-
curred independently of anti-rifampin antibodies, and
the absence of intravascular hemolysis further supports
this view.
Several types of drugs cause ATIN-induced Fanconi syn-
drome, and mitochondrial dysfunction, direct tubular tox-
icity, and immune reactions have been considered to be the
pathogenic mechanisms [4,12,13]. In this patient, a renalbiopsy showed no structural abnormalities of the mitochon-
dria, but demonstrated extensive lymphocytic infiltration
with eosinophils. Immunofluorescent staining also showed
focal deposits of IgA and C3 along the tubules. These find-
ings suggest that hypersensitive immune-mediated injury to
the tubular membrane was the pathogenic mechanism of
Fanconi syndrome, and anti-tubular basement membrane
antibodies have been suggested to induce ATIN in such
cases [10-14].
The coexistence of glomerular and tubular lesions is
relatively rare in drug-induced ATIN. In our patient, the
same immunofluorescent positivity shown in the damaged
tubules was demonstrated in the glomerular mesangium,
and electron-dense deposits were also present in the sub-
endothelial and mesangial spaces. These findings suggest a
relationship between the tubular insult and the immune
injury progressing to the glomeruli. We infer that the re-
lease of tubular antigens as a consequence of rifampin-
induced immunological injury gave rise to superimposed
immune complex deposition in the glomeruli, which pro-
gressed further to IgA nephropathy [15-17].
Hypokalemia is usually mild to moderate in Fanconi syn-
drome [18]. However, profound hypokalemia with muscle
paralysis was the presenting feature in this patient. The
mechanisms of renal potassium wasting were considered to
be as follows. First, the reduced reabsorption of potassium
in the proximal tubule increased the urinary potassium loss.
Second, the bicarbonaturia resulting from the impaired bi-
carbonate reabsorption in the proximal tubule enhanced
the renal potassium excretion [19]. Third, the increased al-
dosterone level in our patient suggested that the reduced
proximal sodium reabsorption increased the distal delivery
of sodium, resulting in the depletion of the extracellular
fluid volume and secondary hyperaldosteronism [20].
The management of drug-induced ATIN includes the
immediate discontinuation of the offending agent and the
use of corticosteroids [12,13]. A short course of cortico-
steroid is usually administered to patients with rifampin-
induced ATIN, and severe renal failure, prolonged renal
failure, or crescentic nephritis increases the need for corti-
costeroids [21,22]. In our case, cessation of the offending
agent without corticosteroid restored the patient’s renal
function and resolved his proteinuria. Furthermore, the
clinical and biochemical presentations of Fanconi syn-
drome were completely reversed. Therefore, we suggest
that the discontinuation of rifampin alone can improve
the ATIN and Fanconi syndrome in such patients, when
the patient shows insidious clinical progress without ser-
ious renal failure or crescentic nephritis.
Conclusion
In conclusion, this case illustrates that rifampin can be
associated with ATIN and Fanconi syndrome, presenting
as hypokalemic paralysis. Therefore, Fanconi syndrome
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associated with rifampin. Renal function, in particular
proximal tubular function, should be closely monitored
when rifampin is used.
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